Business Context and Reporting Period
This Form 8-K reports on events for DFB Healthcare Acquisitions Corp. (not Adapthealth Corp.), a Delaware corporation and emerging growth company. The report covers the period from February 15, 2018, to February 21, 2018, detailing the consummation of its Initial Public Offering (IPO) and related corporate actions.
Key Financial Metrics and Capital Structure
- IPO Proceeds: The Company sold 25,000,000 Units at $10.00 per unit (implied by trust amount), generating gross proceeds of $250,000,000.
- Private Placement: Simultaneously, the Company sold 4,333,333 Private Placement Warrants to the Sponsor (Deerfield/RAB Ventures, LLC) at $1.50 per warrant, generating $6,500,000 in proceeds.
- Trust Account: A total of $250,000,000 from the IPO and Private Placement was deposited into a Trust Account at J.P. Morgan Chase Bank, N.A.
- Warrant Terms: Public Warrants allow the purchase of one share of Common Stock at an exercise price of $11.50 per share. Private Placement Warrants are non-redeemable and exercisable on a cashless basis if held by the original purchaser.
- Capitalization: The amended Certificate of Incorporation authorizes 200,000,000 shares of Common Stock and 1,000,000 shares of Preferred Stock.
Note: As this is a Special Purpose Acquisition Company (SPAC) at the IPO stage, traditional operating metrics such as revenue, profit, operating margins, and debt are not applicable. The filing does not provide values for these items.
Material Changes and Corporate Actions
- Board Appointments: Effective February 15, 2018, Steven Hochberg, Dr. Mohit Kaushal, Dr. Gregory Sorensen, and Dr. Susan Weaver were appointed to the Board of Directors.
- Charter Amendment: The Company filed an amended and restated Certificate of Incorporation on February 15, 2018.
- Agreements Executed: The Company entered into multiple agreements including an Underwriting Agreement (with Goldman Sachs & Co. LLC and Deutsche Bank Securities Inc.), an Investment Management Trust Agreement, and various agreements with the Sponsor and officers.
Outlook, Risks, and Contingencies
- Business Combination Deadline: The Company has 24 months from the closing of the IPO to complete an initial business combination.
- Redemption Rights: If the Company fails to complete a business combination within 24 months, it must redeem 100% of its public shares. Funds in the Trust Account are generally restricted until a business combination is completed or a redemption event occurs.
- Working Capital: The Company may withdraw interest income from the Trust Account to pay taxes and fund working capital requirements, subject to an annual limit of $250,000.
- Transfer Restrictions: Private Placement Warrants are subject to transfer restrictions until 30 days after the completion of the initial business combination.
Investor Verification Checklist
- Verify the exact exercise price ($11.50) and terms of the Public Warrants versus the Private Placement Warrants.
- Confirm the 24-month deadline for completing a business combination and the consequences of failure (liquidation/redemption).
- Review the Underwriting Agreement for details on underwriting discounts and commissions not explicitly detailed in the summary text.
- Examine the Amended and Restated Certificate of Incorporation (Exhibit 3.1) for specific provisions regarding stockholder rights and redemption.
- Confirm the identity and background of the newly appointed directors and the Sponsor (Deerfield/RAB Ventures, LLC).